NOS2 and triple-negative breast carcinoma: In particular, iNOS overexpression is thought to be a predictor of poor outcomes in TNBC (Triple Negative Breast Cancer) patients, as it is associated with decreased relapse-free survival (Glynn et al., 2010), and iNOS can modulate many potential therapeutic targets for TNBC (Walsh et al., 2016).